Clinical Trials Market
Market Insights on Clinical Trials covering sales outlook, demand forecast & up-to-date key trends
Clinical Trials Market By Area (Oncology, Infectious Disease, Metabolic Disorders), Phase (Phase 0, Phase IV), Sponsor (Industry-sponsored, Government / Public, Non-governmental Organizations) & Region Forecast to 2019 - 2029
Clinical Trials Market Outlook
[179 Pages Report] GlobalClinical Trials Marketspending was valued at US$ 95 billion in 2019, and is expected to record a 4% compound annual growth rate (CAGR) through 2029.
Attributes |
Details |
Estimated Market Size (2019) |
US$ 95 Bn |
Global Spending on Clinical Trials by Europe and North America (2018) |
80% |
CAGR (2019-2029) |
4% |
Due to well-established clinical infrastructure and the preference of trial sponsors and collaborators to conduct the Clinical Trials Market in countries with a robust regulatory landscape, Europe and North America accounted for 80% of worldwide spending on Clinical Trials in 2018.
Except for China, where the number of clinical trials for cardiovascular indications outpaced those in the United States in 2018, the country is one of the most popular destinations for clinical trials across various therapy areas.
Let us know your requirement to get
100% FREE customization
Key Factors Shaping the Clinical Trials Market Landscape
Spending on Oncology Drugs Remains High, Despite Complexities
Clinical trials for various oncology indications accounted for approximately 30% of all trials registered, also representing the therapeutic indication with the most number of drug launches. Most of the top industry sponsors of clinical trials allocated a significant proportion of their R&D expenditure to the oncology drug portfolio.
在各种肿瘤的迹象,非小细胞lung cancer (NSCLC) and breast cancer were predominantly targeted for clinical development. However, clinical trials market for oncology are steadily becoming more complex in terms of patient recruitment, clinical trial design parameters such as endpoints, narrower eligibility criteria, among others.
Growing Focus on Enhancing Clinical Trial Design Using Predictive Analytics
Predictive analytics tools including artificial intelligence and machine learning are already being used in several companies to develop models and guide decisions. Considering the plethora of health data currently available to clinical trial investigators, predictive analytics tools can be effectively leveraged in clinical trial design to identify patient characteristics that are more likely to respond to a specific treatment pattern, thereby increasing the success rates and reducing risk to large, multi-center clinical trials.
It can also aid in the development of precision approaches by assessing the effect of a certain therapeutic approach on a subset of patient population based on certain biomarkers. The potential for predictive analytics to influence clinical trial design is likely to hinge on the understanding of complex disease models by clinical trial investigators, and collaborative efforts are still underway to unlock the maximum impact on clinical development.
Developing Countries Offer Unprecedented Value to Clinical Trial Sponsors
Despite a third of all clinical trials market registered are located in the U.S., clinical trial sponsors have been offshoring clinical trials market to countries such as China, India, Russia, and Brazil for the past few years. These countries are attractive for several reasons: a large patient pool, well-developed healthcare infrastructure in urban areas, an abundance of skilled clinical staff for monitoring clinical trials, among other factors.
Governments in certain countries are also offering incentives for clinical trial sponsors to carry out clinical trials in these countries, which typically tend to be shorter and thus, also cost-effective. There have also been several ethical questions raised pertaining to clinical trials in developing countries, which put a damper on offshoring clinical trials.
Clinical Trials Landscape: Stakeholder Assessment
- A significant proportion of clinical trials were initiated by large pharmaceutical companies, with Bristol-Myers Squibb, AstraZeneca, Merck & Co., Roche, and Johnson & Johnson rounding out the top 5 in terms of the number of trials.
- Emerging pharmaceutical and biotechnology companies are continuing to exert their influence on the clinical trials sector, with a robust pipeline of therapeutic agents paving the way.
- Companies such as Bristol-Myers Squibb, Merck & Co., Amgen, and some others focused their efforts on clinical trials for currently approved drugs to obtain marketing expansion, while companies such as AstraZeneca, GlaxoSmithKline, Johnson & Johnson, among others have a greater focus on drugs with no prior marketing authorization.
- While assessing the therapeutic area focus, most companies heavily depended on oncology, where the number of clinical trials initiated was disproportionately large compared to the rest of their respective portfolios. Only a limited number of companies had a diverse allocation of therapeutic focus.
Find your sweet spots for generating winning opportunities in this market.
Talk to Analyst‘Clinical Trials’ Metamorphosing into a Connected, Streamlined Landscape
Complexities and data volumes in clinical trials are on a ceaseless rise. There is an urging need for pharma companies to increase R&D efforts, as development costs break records and patent cliffs approach. Integration of cloud and analytics is pervasively evident, anddigital transformation in healthcareare making holistic changes in the clinical trial process.
The healthcare models are undergoing tectonic shifts and seeing massive inflow of new clinical trial models, which are organized, streamlined, and nurture patient engagement. Pharmaceutical companies are pushing the limits of R&D efforts to improvise their clinical trial models, which will help them cope up with ever-increasing developmental costs.
The New-Age Clinical Trials Are ‘Web’ Based
Biopharmaceutical companies are focused on implementing digital health in the clinical trials and operations. It is highly likely that pilot projects and investments to validate digital measures will continue to rise, abreast the uptake of patient centricity to empower convenient and personalized approaches.
The initial years of the ‘digitalization era’ also left some major imprints on the clinical trials landscape. Pzifer has already started focusing on new launches of web-based clinical trial outreach platforms, and other companies followed suit. Such efforts mark a new milestone for the global clinical trials space and fine tune the way clinical trials were conducted.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
North America and Europe – The Goldilocks Zone
North America and Europe present a favorable and standardized ecosystem for the clinical trials landscape – collectively estimated to create an opportunity worth ~ US$ 76 Bn in 2019. These regions often gain the first mover advantage in almost every technological disruption in light of their economic vigor; and in case of clinical trials, pharmaceutical giants are adopting artificial intelligence to disrupt all stages of the process – from linking eligible patients to respective studies, to monitoring data collection and adherence.
The Broader Perspective
The clinical trials landscape is witnessing a revolutionary phase, where new sources of data are being generated and put in the hands of patients. Pharma and medical device companies are emphasizing to bridge the gap between current scope of patient access at present and future, to help them maintain a healthy lifestyle.
As today’s clinical trials are way more sophisticated than the previous ones, the clinical trials landscape has been spectating persistent reformations to ensure that the essential supplies of patient kits are in right place at right time. High focus is also being placed on adaptive trial designs, which eases mid-study modifications based on accumulated data.
How Growth Will Unfold?
Faster clinical trials are crucial for pharma and medical device companies, as these are time- and capital-intensive. Spending on phase III clinical trials remains comparatively higher than phase II and phase I trials, owing to their greater complexity and need for larger patient pool.
Sponsors are highly likely to see greater room for success in developing regions, such as South Asia and East Asia. Moreover, the conduction of clinical trials across this fast-growing regions promises a new shade of advantages, including tax incentives and efficient regulatory pathways.
关键的部分
By Area:
- Oncology
- Infectious Disease
- Metabolic Disorders
- Cardiovascular
- Neuroscience
- Respiratory
- Others
By Phase:
- Phase 0
- Phase I
- Phase II
- Phase III
- Phase IV
By Sponsor:
- Industry-sponsored
- Government / Public
- Non-governmental Organizations
- Others (Academic Medical Centers, Individuals, etc.)
By Region:
- North America
- Latin America
- Europe
- 东Asia
- South Asia
- Oceania
- Middle East & Africa
Frequently Asked Questions
The clinical trials market was valued at US$ 95 Bn by 2019, and is advancing at a CAGR of 4%.
Chiltern, Omnicare, PPD, Parexel, Kendle, and Quintles, are some of the leading companies in the clinical trials market.
1. Executive Summary
1.1. Global Industry Outlook
1.2.行业趋势
1.3. Analysis and Recommendations
2. Market Overview
2.1. Sector Coverage / Taxonomy
2.2. Definition / Scope / Limitations
2.3. Key Phases in Clinical Trials
2.4. Clinical Trials for Pharmaceutical Products v/s Medical Devices
3. Key Market Trends
3.1. Key Trends Impacting the Sector
3.2. Regulatory Trends
4. Key Success Factors
5. Global Clinical Trials Landscape and Analysis 2014-2018 and Outlook, 2019-2029
5.1. Historical Number of Trials, 2009-2019, by Disease Area and Region
5.2. Analysis of Clinical Trials by Sponsor, 2009-2019
5.3. Analysis of Clinical Trials by Phase, 2009-2019
5.4. Current and Future Trial Projections, 2019-2029
6. Global Clinical Trials Landscape – Economic Impact and Trial Cost Structure Analysis
6.1. Regional Average Per-Patient Clinical Trial Costs
6.2. Cost Components of Clinical Trials
6.3. Economic Impact Analysis of Clinical Trials
6.3.1. Direct Impact
6.3.2. Indirect and Induced Impact
7. Global Clinical Trials Spending (in US$ Mn) Analysis 2014-2018 and Outlook, 2019-2029
7.1. Historical Spending (US$ Mn) Analysis, 2014-2018
7.2. Current and Future Spending (US$ Mn) Projections, 2019-2029
7.3. % of Overall R&D Expenditure Attributable to Clinical Trials
8. Market Background & Context
8.1. Essential Fundamentals of Clinical Trials
8.2. Trial Design Considerations
8.3. Impact of Digitization on Clinical Trials
8.4. Macro-Economic Indicators
8.4.1. Global GDP Growth Outlook
8.4.2. R&D Investment as a % of GDP
8.4.3. Number of Researchers
8.4.4. Number of Hospitals & Hospital Beds
8.4.5. Number of Diagnostic Labs
8.5. Forecast Factors - Relevance & Impact
8.6. Key Stakeholders in Clinical Trials & Interplay
8.6.1. Public Sector Institutions
8.6.2. Private Institutions / Individuals
8.6.3. Drug & Device Manufacturers
8.6.4. Contract Research Organizations
8.6.5. Institutional Review Boards
8.6.6. IT Infrastructure Providers
8.6.7. Hospitals & Healthcare Facilities
8.6.8. Others
8.7. Industry Dynamics
8.7.1. Drivers
8.7.2. Challenges
8.7.3. Opportunities
9. Global Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029, By Sponsor
9.1. Introduction / Key Findings
9.2. Historical Number of Trials and Expenditure (US$ Mn) By Sponsor, 2014-2018
9.3. Current and Future Number of Trials and Expenditure (US$ Mn) and Forecast By Sponsor, 2019 - 2029
9.3.1. Industry-sponsored
9.3.2. Government / Public
9.3.3. Non-governmental Organizations
9.3.4. Others
10. Global Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029, By Area
10.1. Introduction / Key Findings
10.2. Historical Number of Trials and Expenditure (US$ Mn) By Area, 2014-2018
10.3. Current and Future Number of Trials and Expenditure (US$ Mn) and Forecast By Area, 2019 - 2029
10.3.1. Oncology
10.3.2. Infectious Disease
10.3.3. Metabolic Disorders
10.3.4. Cardiovascular
10.3.5. Neuroscience
10.3.6. Respiratory
10.3.7. Others
11. Global Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029, By Stage
11.1. Introduction / Key Findings
11.2. Historical Number of Trials and Expenditure (US$ Mn) By Stage, 2014-2018
11.3. Current and Future Number of Trials and Expenditure (US$ Mn) and Forecast By Stage, 2019 - 2029
11.3.1. Phase 0
11.3.2. Phase I
11.3.3. Phase II
11.3.4. Phase III
11.3.5. Phase IV
12. Global Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029, By Region
12.1. Introduction
12.2. Historical Number of Trials and Expenditure (US$ Mn) By Region, 2014-2018
12.3. Current Number of Trials and Expenditure (US$ Mn) and Forecast By Region, 2019 - 2029
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
13. North America Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029
13.1. Introduction
13.2. Regulatory Scenario
13.3. Historical Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2014-2018
13.4. Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2019 - 2029
13.4.1. By Country
13.4.1.1. U.S.
13.4.1.2. Canada
13.4.2. By Sponsor
13.4.3. By Area
13.4.4. By Stage
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
14. Latin America Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029
14.1. Introduction
14.2. Regulatory Scenario
14.3. Historical Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2014-2018
14.4. Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2019 - 2029
14.4.1. By Country
14.4.1.1. Brazil
14.4.1.2. Mexico
14.4.1.3. Argentina
14.4.1.4. Rest of Latin America
14.4.2. By Sponsor
14.4.3. By Area
14.4.4. By Stage
14.5.市场趋势
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
15. Europe Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029
15.1. Introduction
15.2. Regulatory Scenario
15.3. Historical Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2014-2018
15.4. Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2019 - 2029
15.4.1. By Country
15.4.1.1. Germany
15.4.1.2. Italy
15.4.1.3. France
15.4.1.4. U.K.
15.4.1.5. Spain
15.4.1.6. BENELUX
15.4.1.7. Russia
15.4.1.8. Poland
15.4.1.9. Rest of Europe
15.4.2. By Sponsor
15.4.3. By Area
15.4.4. By Stage
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
16.东Asia Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029
16.1. Introduction
16.2. Regulatory Scenario
16.3. Historical Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2014-2018
16.4.许多试验和支出(美元Mn)Market Taxonomy, 2019 - 2029
16.4.1. By Country
16.4.1.1. China
16.4.1.2.Japan
16.4.1.3. South Korea
16.4.2. By Sponsor
16.4.3. By Area
16.4.4. By Stage
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
17. South Asia Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029
17.1. Introduction
17.2. Regulatory Scenario
17.3. Historical Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2014-2018
17.4. Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2019 - 2029
17.4.1. By Country
17.4.1.1. India
17.4.1.2. Thailand
17.4.1.3. Indonesia
17.4.1.4. Malaysia
17.4.1.5. Singapore
17.4.1.6. Rest of South Asia
17.4.2. By Sponsor
17.4.3. By Area
17.4.4. By Stage
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
18.大洋洲的临床试验201年景观分析4-2018 and Outlook 2019-2029
18.1. Introduction
18.2. Regulatory Scenario
18.3. Historical Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2014-2018
18.4. Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2019 - 2029
18.4.1.通过数ry
18.4.1.1. Australia
18.4.1.2. New Zealand
18.4.2. By Sponsor
18.4.3. By Area
18.4.4. By Stage
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
19. Middle East and Africa Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029
19.1. Introduction
19.2. Regulatory Scenario
19.3. Historical Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2014-2018
19.4. Number of Trials and Expenditure (US$ Mn) By Market Taxonomy, 2019 - 2029
19.4.1. By Country
19.4.1.1. GCC Countries
19.4.1.2. Turkey
19.4.1.3. South Africa
19.4.1.4. Rest of Middle East and Africa
19.4.2. By Sponsor
19.4.3. By Area
19.4.4. By Stage
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
20. Emerging Countries Clinical Trials Landscape Analysis 2014-2018 and Outlook 2019-2029
20.1. Introduction
20.1.1. Proportion Analysis of Expenditure, By Key Countries
20.1.2. Growth Comparison of Global Market v/s Emerging Countries
20.2. China Clinical Trials Landscape Analysis
20.2.1.介绍
20.2.2. Regulatory Scenario
20.2.3. PEST Analysis
20.2.4. Proportion Analysis of Expenditure by Market Taxonomy
20.2.5. Number of Trials and Expenditure (US$ Mn) Forecast by Market Taxonomy
20.2.5.1. By Sponsor
20.2.5.2. By Area
20.2.5.3. By Stage
20.2.6. China Clinical Trials Landscape – Stakeholder Landscape
20.3. India Clinical Trials Landscape Analysis
20.3.1. Introduction
20.3.2. Regulatory Scenario
20.3.3. PEST Analysis
20.3.4. Proportion Analysis of Expenditure by Market Taxonomy
20.3.5. Number of Trials and Expenditure (US$ Mn) Forecast by Market Taxonomy
20.3.5.1. By Sponsor
20.3.5.2. By Area
20.3.5.3. By Stage
20.3.6. India Clinical Trials Landscape - Stakeholder Landscape
20.4. Brazil Clinical Trials Landscape Analysis
20.4.1. Introduction
20.4.2. Regulatory Scenario
20.4.3. PEST Analysis
20.4.4. Proportion Analysis of Expenditure by Market Taxonomy
20.4.5. Number of Trials and Expenditure (US$ Mn) Forecast by Market Taxonomy
20.4.5.1. By Sponsor
20.4.5.2. By Area
20.4.5.3. By Stage
20.4.6. Brazil Clinical Trials Landscape - Stakeholder Landscape
21. Key Stakeholder Assessment
21.1. Clinical Trials Share Analysis by Top 20 Companies
21.2. Top 20 Most Valuable R&D Projects, 2018
21.3. Worldwide Pharmaceutical R&D Spend Projections by Key Companies
21.4. Landscape of Key Stakeholders in Clinical Trials
21.4.1. Clinical Research Partners
21.4.2. Clinical Data Management Providers
22. Assumptions and Acronyms Used
23. Research Methodology
Let us know your requirement to get
100% FREE customization
Table 01: Global Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Sponsor Type
Table 02: Global Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Area Type
Table 03: Global Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Phase
Table 04: Global Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Region
Table 05: North America Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Sponsor Type
Table 06: North America Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Area Type
Table 07: North America Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Phase
Table 08: North America Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 09: Latin America Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Sponsor Type
Table 10: Latin America Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Area Type
Table 11: Latin America Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Phase
Table 12: Latin America Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 13: Europe Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Sponsor Type
Table 14: Europe Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Area Type
Table 15: Europe Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Phase
Table 16: Europe Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 17: East Asia Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Sponsor Type
Table 18: East Asia Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Area Type
Table 19: East Asia Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Phase
Table 20: East Asia Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 21: South Asia Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Sponsor Type
Table 22: South Asia Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Area Type
Table 23: South Asia Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Phase
Table 24: South Asia Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 25: Oceania Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Sponsor Type
Table 26: Oceania Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Area Type
Table 27: Oceania Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Phase
Table 28: Oceania Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Table 29: MEA Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Sponsor Type
Table 30: MEA Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Area Type
Table 31: MEA Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Phase
Table 32: MEA Spending on Clinical Trials (US$ Bn) Analysis 2014–2018 and Forecast 2019–2029, By Country
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystFigure 01: Global Spending on Clinical Trial (US$ Bn) Analysis, 2014–2018
Figure 02: Global Spending on Clinical Trials (US$ Bn) Forecast & Y-o-Y Growth (%), 2019–2029
Figure 03: North America Spending on Clinical Trial (US$ Bn) Analysis, 2014–2018
Figure 04: North America Spending on Clinical Trials (US$ Bn) Forecast & Y-o-Y Growth (%), 2019–2029
Figure 05: Latin America Spending on Clinical Trial (US$ Bn) Analysis, 2014–2018
Figure 06: Latin America Spending on Clinical Trials (US$ Bn) Forecast & Y-o-Y Growth (%), 2019–2029
Figure 07: Europe Spending on Clinical Trial (US$ Bn) Analysis, 2014–2018
Figure 08: Europe Spending on Clinical Trials (US$ Bn) Forecast & Y-o-Y Growth (%), 2019–2029
Figure 09: East Asia Spending on Clinical Trial (US$ Bn) Analysis, 2014–2018
Figure 10: East Asia Spending on Clinical Trials (US$ Bn) Forecast & Y-o-Y Growth (%), 2019–2029
Figure 11: South Asia Spending on Clinical Trial (US$ Bn) Analysis, 2014–2018
Figure 12: South Asia Spending on Clinical Trials (US$ Bn) Forecast & Y-o-Y Growth (%), 2019–2029
Figure 13: Oceania Spending on Clinical Trial (US$ Bn) Analysis, 2014–2018
Figure 14: Oceania Spending on Clinical Trials (US$ Bn) Forecast & Y-o-Y Growth (%), 2019–2029
Figure 15: MEA Spending on Clinical Trial (US$ Bn) Analysis, 2014–2018
Figure 16: MEA Spending on Clinical Trials (US$ Bn) Forecast & Y-o-Y Growth (%), 2019–2029
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
